Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy

By V. McLaughlin, A. Shillington, S. Rich. Circulation, 2002

1,279 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) (2009, result): “Based on the results of RCTs and two large long term observational studies, which have documented an improvement in survival of patients with iPAH treated with epoprostenol [56,57], intravenous epoprostenol has been approved by FDA for treatment of severe (WHO class III or IV) PAH.”
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008, background): “The 3-year survival rate for patients receiving intravenous epoprostenol monotherapy was 63% (31, 32).”
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. (2007, result): “Reports on the prognostic value of PAP have contradicted each other.(2,3) Sitbon et al.”
Pulmonary arterial hypertension (2013, background): “Long term effectiveness has never been evaluated prospectively but retrospective analysis comparing patients treated by intravenous epoprostenol with data from patients treated with conventional therapy find meaningful clinical benefit for patients in NYHA FC III or IV [201,214,218,219].”